Navigation Links
Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
Date:11/14/2011

has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule wholly-owned by Nektar, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel proprietary topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development stage products that leverage Nektar's proprietary technology platform include peginesatide, for which Affymax and partner Takeda submitted an NDA to the FDA in May 2011, and Baxter's BAX 855, a long-acting PEGylated rFVIII program planned to enter Phase 1 clinical development in 2011.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:Karen Bergman/BCC Partners

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
2. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
5. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
6. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
8. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
9. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , August 19, 2014 Elbit ... EMITF ) announced today that Elbit Medical Technologies ... Company in which it holds approximately 86% of the ... Cell Ltd., in which Elbit Medical holds approximately 30.8% ... majority of Gamida Cell,s shareholders (including Elbit Medical), signed ...
(Date:8/18/2014)... , August 19, 2014 ... cell expansion technologies and therapeutic products, announced today that it ... Pharma AG  ( " Novartis " ... $35 million in Gamida Cell and in return will receive ... The option is exercisable for a limited period of time ...
(Date:8/18/2014)... YORK , Aug. 18, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Biopharmaceutical Markets ... be categorized into three types: chromatography, membranes/filters ... products is increasing and fueling growth of ...
Breaking Medicine Technology:Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 2Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 3Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... Cempra Pharmaceuticals today announced results from its Phase ... tolerability of oral administration of our fourth generation ... with oral levofloxacin for the treatment of community-acquired ... CEM-101 demonstrated efficacy comparable to levofloxacin and a ...
... Sept. 15, 2011 Reportlinker.com announces that ... in its catalogue: Global ... http://www.reportlinker.com/p0240543/Global-Blood-Glucose-Test-Strips-Market-2010-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic ... Test Strips market to grow at a ...
Cached Medicine Technology:Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3Global Blood Glucose Test Strips Market 2010-2014 2
(Date:8/19/2014)... Skmen.com, an outstanding company in the garment industry, has unveiled ... addition to this, the company has also launched a big ... available at low rates, up to 30 percent off. ... beautiful bohemian outfits are available in many colours, including green, ... top quality clothes, reasonable prices and sincere service, the company ...
(Date:8/19/2014)... 2014 Recently, CanadaGooseJackor.nu, a popular supplier of ... Canada Goose Solaris Parkas . All clients that place ... discounted price (up to 35% off) before the end of ... in an online supplier’s business. CanadaGooseJackor.nu is a great platform ... all over the world can enjoy its dedicated professional service ...
(Date:8/19/2014)... LunaDress, a popular supplier of fashionable wedding, bridesmaid, ... now providing a discount of up to 67% on ... white prom outfits are available in different necklines; ladies ... , There are over 400 cheap white prom dresses ... offer is valid until August 29, 2014. The discounted ...
(Date:8/19/2014)... Recently, UWDress.com, a professional company of women’s dresses ... plus size formal evening dresses . Additionally, the firm has ... At the moment, all of them can be ordered at ... be valid until August 27, 2014. , The company ... designers believe that women of all shapes can be graceful ...
(Date:8/19/2014)... Recently, iFitDress.com,a leading online supplier of ... its new collection of pewter evening dresses . ... company’s global market. Each item is carefully made with ... spokesman, customers that have specific requirements can also order ... the brand new items are offered at discounted prices, ...
Breaking Medicine News(10 mins):Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:High Quality Canada Goose Solaris Parkas For Sale At CanadaGooseJackor.nu 2Health News:Popular Supplier LunaDress Providing an Exclusive Assortment of White Prom Dresses at a Discount of Up to 67% 2Health News:Cheap Plus Size Formal Evening Dresses Announced By UWDress.com 2Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2
... boost survival, German study shows , MONDAY, June ... performing radical hysterectomy in early-stage cervical cancer patients ... tumor recurrence, a German study shows. , The ... modified version of traditional radical hysterectomy. But this ...
... Plan Takes Holistic Approach in Seeking New Solutions to Improve ... Calif., June 1 More than 200 physicians and nurses ... to address a myriad of issues surrounding geriatric care in ... dementia and prostate cancer to more process-oriented issues such as ...
... 1, 2009) The latest advances in polyp detection, ... colonoscopy will be presented today at Digestive Disease Week ... size and type of polyps detected during colonoscopy and ... insight into the recommended frequency of follow-up preventive colonoscopy. ...
... heartbeat can indicate distress, but currently there is no ... when it could be too late to prevent serious ... system developed by an MIT scientist and colleagues including ... fetal heartbeat. The additional researchers are from the Institut ...
... , - John Hancock AnnuityNote Variable Annuity offers a simplified ... Market participation with downside protection , , - Simple ... John Hancock today announced the launch of a new retirement ... income to a broader market beyond the reach of traditional ...
... and the Alzheimer,s Association Support Award to Recognize Critical Role ... N.J., June 1 Eisai Inc., ... Alzheimer,s disease and their caregivers across America to nominate local ... A lzheimer,s. R ecognition of E xcellence.) Pharmacy ...
Cached Medicine News:Health News:Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 2Health News:Physicians Join With National Healthcare Leaders to Explore New Ways to Enhance Geriatric Care in America 3Health News:New research identifies more effective tools for detection of colorectal cancer 2Health News:New research identifies more effective tools for detection of colorectal cancer 3Health News:New research identifies more effective tools for detection of colorectal cancer 4Health News:New research identifies more effective tools for detection of colorectal cancer 5Health News:New research identifies more effective tools for detection of colorectal cancer 6Health News:New research identifies more effective tools for detection of colorectal cancer 7Health News:MIT: New system monitors fetal heartbeat 2Health News:MIT: New system monitors fetal heartbeat 3Health News:John Hancock Launches New Retirement Income Solution 2Health News:John Hancock Launches New Retirement Income Solution 3Health News:John Hancock Launches New Retirement Income Solution 4Health News:John Hancock Launches New Retirement Income Solution 5Health News:Call for Nominations for the 2009 C.A.R.E. Pharmacy Award 2Health News:Call for Nominations for the 2009 C.A.R.E. Pharmacy Award 3
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
... offered as either EDTA K2 or ... calcium ions and therefore blocks the ... in an EDTA anticoagulated blood sample ... hours. EDTA tubes are for the ...
... is a ubiquitous enzyme that catalyzes ... is also the specific protein that ... immunofluorescence (EMA) tests (Bio-Rad catalog number ... serologic tests are highly sensitive and ...
... blood oximeters provide cardiologists with critical ... a patient's blood. The Oxicom series ... over a half-million saturation samples measured ... cost-effective oxygen saturation readings in less ...
Medicine Products: